Hepatitis B Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Chemo Therapy, Immunosuppressant Therapy, Nucleoside Analogue), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region Forecast 2020-2031

Hepatitis B Treatment Market size was valued at US$ 3.4 billion in 2024 and is expected to reach US$ 4.5 billion by 2031, growing at a significant CAGR of 3.8% from 2025-2031. Hepatitis-B is also known as serum hepatitis which is an infectious disease of the liver caused by the Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic kidney disease (ckd) drugs. In this condition, the virus interferes with the hepatocytes and the liver becomes inflamed.

Hepatitis B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. The Hepatitis B virus is unable to cross the skin or mucous membranes. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and hemodialysis patients easily develop an infection with the Hepatitis-B Virus. The symptoms of Hepatitis B do not develop until after a few weeks of exposure. The severity of Hepatitis may cause cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.

Geographically, the market is in the growing stage, as various government organizations are initiating awareness programs to prevent hepatitis B infection. An increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the market. According to the World Health Organization, there are currently 240 million chronic carriers of the hepatitis B virus of which approximately 1525% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as the U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in the global market.

For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio's highly optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, Moreover, various drugs for hepatitis B treatment in the pipeline are also expected to propel the hepatitis B treatment industry over the forecast period.

Key Developments

• In January 2017 Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy (tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg)
• In December 2016, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection